MENU
Sri Lanka has been selected to participate in the MOONRAKER Program, an investigator-initiated clinical trial evaluating finerenone for heart failure. This collaboration, led by The George Clinical, CPC Clinical Research, RemediumOne, and the University of Kelaniya – Sri Lanka, focuses on generating clinical evidence for treatment strategies.
The program aims to gain a comprehensive understanding of the potential of finerenone for the treatment of heart failure, examining its efficacy and safety across a broad spectrum of patients and clinical settings.
REDEFINE-HF – Testing finerenone in patients hospitalized for acute heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) https://slctr.lk/trials/slctr-2024-022
CONFIRMATION-HF – Evaluating early initiation of combination therapy with finerenone and SGLT2 inhibition in patients hospitalized for acute heart failure regardless of ejection fraction
FINALITY-HF – Assessing finerenone in patients with heart failure and reduced ejection fraction (HFrEF) who are not eligible for treatment with steroidal mineralocorticoid receptor antagonists (MRAs).
Finerenone, a non-steroidal MRA, is being studied for its role in managing cardiovascular and renal complications in heart failure. Mineralocorticoid receptor (MR) overactivation contributes to cardiovascular and kidney damage. Finerenone being tested offers protection as it selectively binds to the MR receptor, blocking harmful effects of MR overactivation.
RemediumOne and the University of Kelaniya are working with George Clinical and CPC Clinical Research to conduct these studies across 12 trial centres in Sri Lanka and contribute to scientific evidence in heart failure treatment.
Study sites include:
The REDEFINE-HF trial is currently recruiting patients, while the other two trials are in the regulatory submission phase in Sri Lanka.
Stay tuned for more updates!